2seventy bio Inc (TSVT) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch...

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast...

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a...

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

- Company Now Exclusively Focused on Development and Commercialization of Abecma - 2seventy bio, Inc. (Nasdaq: TSVT), announced today the...

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton...

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress

New strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in...